Article Text

Download PDFPDF

O-055 Selective middle meningeal artery bevacizumab injection for chronic subdural hematoma: an early experience in twelve hemispheres
Free
  1. J Khalife
  1. Neurology, Cooper University Health, Camden, NJ

Abstract

Background Chronic subdural hematoma (cSDH) has a rising incidence associated with an increasing burden of disability and mortality worldwide. Vascular endothelial growth factor (VEGF) plays an integral role in the inflammation and formation of subdural membranes responsible for the origin and propagation of cSDH. We report an early experience of intra-arterial bevacizumab, a VEGF receptor antagonist, to the middle meningeal artery of twelve hemispheres in eight patients with cSDH.

Methods Eight patients with either unilateral or bilateral cSDH received intra-arterial infusion of 2 mg/kg bevacizumab into the middle meningeal artery of each treated hemisphere. The primary outcome was hematoma recurrence or re-accumulation requiring surgical drainage or middle meningeal artery embolization (MMAE) within 3 months post treatment.

Results Of 12 hemispheres treated, no treatment-related complications were reported. Median duration of follow-up was 5 months (interquartile range [IQR] 3–7.5). By 3 months post treatment, no patients experienced hematoma recurrence or re-accumulation. One patient required concurrent evacuation at the time of bevacizumab administration. There were no major strokes or mortality within 1 month. Four hemispheres (33.3%) demonstrated complete radiographic hematoma resolution by 3 months. All hemispheres achieved 50% reduction in hematoma size by 3 months.

Conclusions For all hemispheres treated, there were no hematoma recurrence or progression requiring surgical drainage or MMAE within 3 months except one who required concurrent evacuation 24 hours after treatment. Our initial experience supports bevacizumab as a novel, potentially viable agent for cSDH treatment in select patients. Future studies in larger cohorts are necessary to confirm efficacy and safety and appropriate dosing.

Disclosures J. Khalife: None.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.